B chronic lymphocytic leukemia (B-CLL) is characterized by the relentless accumulation of monoclonal mature CD5 ϩ / CD19 ϩ B cells in lymphoid organs, bone marrow, and peripheral blood [1] . Virtually all circulating B-CLL lymphocytes are arrested in the G0/early G1 phase of the cell cycle; however, a proliferating compartment is present in specialized structures called pseudo-follicles that are located in lymph nodes and bone marrow of B-CLL patients [1, 2] . Engagement of the TNFR superfamily member 5 (CD40), which is expressed throughout B cell development, has been shown to up-regulate the expression of costimulatory surface molecules on malignant B cells, which results in increased antigen-presenting capacity of indolent B cell malignancies [3] . However, a major adverse effect of CD40 ligation is its ability to up-regulate the expression of several antiapoptotic genes and to induce B-CLL proliferation [4 -6] . In this respect, also, synthetic CpG-oligodeoxynucleotides (CpG-ODN), which mimic CpG motifs present in unmethylated bacterial DNA and are recognized by TLR9, up-regulate the expression of costimulatory surface molecules of malignant B cells in vitro [7] [8] [9] [10] . At variance to CD40 ligation, immune stimulation with CpG-ODN has been described to be accompanied by antiapoptotic and proapoptotic effects in indolent B cell malignancies [7] [8] [9] [10] [11] , and a phase I trial of CpG-ODN is ongoing in B-CLL patients, irrespective of cytogenetic or mutational status [12] . Recent studies have demonstrated that the small molecules, Nutlins, which represent potent and selective inhibitors of p53/murine double minute 2 interaction [13] , effectively induce apoptosis in B-CLL when used alone or in combination with chemotherapeutic agents [14, 15] and also impair angiogenesis, at least in vitro [16] .
On these bases, the aim of our study was to investigate the effect of combined treatment of CpG-ODN plus Nutlin-3 on relevant clinical parameters, such as immune activation, cell cycle progression, and apoptosis in B-CLL cells. For this purpose, peripheral blood samples were collected in heparincoated tubes from 10 patients ( Table 1) fulfilling diagnostic criteria for B-CLL in agreement with institutional guidelines. The B-CLL patients were characterized for a number of clinical parameters, such as stage of the disease, according to the Rai classification, doubling time, levels of Zap-70, whose high expression represents an important negative prognostic marker [17, 18] , and p53 status (Table 1) . PBMC from B-CLL patients were processed as described previously [14] , with a purity Ͼ90% of resulting CD19 ϩ B cells. All samples were p53 wild-type (Table 1) , a requisite for optimal response to Nutlin-3 cytotoxicity [14, 15] . B-CLL samples were cultured at a density of 1 ϫ 10 6 cells/ml in RPMI containing 10% FBS. Cells were left untreated or treated with 5 g/ml CpG-ODN (C-class ODN 2395, Coley Pharmaceutical, Wellesley, MA, USA) [19] in the presence of 10 M Nutlin-3 (Cayman Chemical, Ann Arbor, MI, USA) or of control vehicle (0.1% DMSO). The expression levels of Zap-70, as well as the induction of p53 by Nutlin-3, were determined by Western blot analysis, using antibodies from Upstate Biotechnology (Lake Placid, NY, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Flow cytometry analysis of activation markers (CD54, CD69, CD80, CD86, MHC-II), of MHC-I, as well as of the death receptors CD95 and TRAIL receptor 2 (TRAIL-R2) was performed by using FITC-or PE-conjugated mAb from Becton Dickinson (San Jose, CA, USA), R&D Systems (Minneapolis, MN, USA), or Immunotech (Marseille, France). Assessment of cycle progression and apoptosis levels was analyzed by BrdU incorporation and annexin V/propidium iodide (PI), respectively, performed as described previously [14, 16] .
CpG-ODN maximally up-regulated the expression of a variety of immune accessory molecules, such as CD54, CD69, CD80, CD86, and MHC-II, in all B-CLL samples after 48 h of treatment (Fig. 1A) . Of note, CpG-ODN induced an efficient immune activation irrespectively of the Zap-70 status of the B-CLL samples, as exemplified in Figure 1A . Importantly, Nutlin-3 alone did not modulate the expression of activation markers, and when added simultaneously to CpG-ODN, it did not interfere with the ability of CpG-ODN to up-regulate the surface activation markers (data not shown). On the other hand, Nutlin-3 alone significantly (PϽ0.05) up-regulated the expression of the death receptors CD95 and TRAIL-R2 (Fig. 1B , shaded bars), two known p53 targets [20] , and the combined treatment of Nutlin-3 plus CpG-ODN significantly (PϽ0.05) enhanced CD95 expression further with respect to Nutlin-3 alone (Fig. 1B, open bars) . A potential drawback of immune stimulation is the possibility to promote antiapoptotic pathways and thus, to increase the proliferative pool of B-CLL, especially in patients with worse prognostic factors [4 -9, 17, 18] . However, treatment with CpG-ODN has also been shown to elicit a heterogeneous response as a result of the simultaneous induction of B-CLL proliferation and apoptosis [10 -12] . Thus, to evaluate the net balance between proliferation and apoptosis, which represents a relevant biological parameter, we have analyzed the number of viable B-CLL cells after 48 -96 h of exposure to CpG-ODN ( Fig. 2A) . This time-frame was selected on the basis of preliminary experiments, in which a high variability, in terms of cell viability, became evident from sample to sample after Day 4 of culture, when most of the cultures rapidly died, irrespectively of the presence in culture of CpG-ODN (data not shown), hampering a reliable evaluation of the effects of Nutlin-3.
Treatment with CpG-ODN induced a progressive decline in the total number of viable cells with respect to unstimulated cultures ( Fig. 2A, open bars) . As Nutlin-3 has been shown to inhibit the cell cycle progression and/or to induce apoptotic cell death depending on the cell model investigated [13] [14] [15] [16] , the cell cycle profile was investigated in B-CLL samples stimulated for 48 h with CpG-ODN in the absence or presence of Nutlin-3. As shown in Figure 2B , treatment of B-CLL cells with CpG-ODN induced a significant (PϽ0.05) increase of BrdU uptake (from 2.9Ϯ2.3% in unstimulated to 16.2Ϯ8.3% in CpG-ODN-stimulated B-CLL samples; meansϮSD of five separate experiments). Of note, the increase in BrdU uptake induced by CpG-ODN stimulation was counteracted significantly (PϽ0.05) by Nutlin-3 (4.5Ϯ2.3% in B-CLL samples treated with CpG-ODNϩNutlin-3; meansϮSD of five separate experiments; Fig. 2B ). In parallel, the degree of apoptosis was evaluated by annexin-V/PI double-staining (Fig. 2C) . Nutlin-3 promoted apoptosis significantly (PϽ0.05) in unstimulated (from 5Ϯ2.3% in vehicle-treated to 22Ϯ5.5% in Nutlin-3-treated B-CLL samples; meansϮSD of 10 separate experiments) and CpG-ODN-stimulated B-CLL cultures (from 7Ϯ3.1% in vehicle-treated to 25Ϯ7.3% in Nutlin-3-treated B-CLL samples; meansϮSD of 10 separate experiments).
Current treatment regimens for indolent B cell malignancies use alkylating agents, purine analogs, mAb, or combinations thereof [21] . Such combination therapies result in greater response rates than those seen with single, agent-based therapy alone, but none of these therapies is curative. Among innovative, therapeutic approaches, the use of CpG-ODN for immunotherapy has recently entered the phase I trial in B-CLL patients [12] . In this respect, the central finding of this study was that Nutlin-3, a potent, nongenotoxic activator of the p53 pathway [13] , induced a comparable cytoxicity in quiescent B-CLL cells as well as in B-CLL cells immune-stimulated with CpG-ODN, without interfering with the ability of CpG-ODN to induce immune activation. Moreover, we found that the treatment with CpG-ODN plus Nutlin-3 did not interfere and rather potentiated the expression of the death receptors CD95 and TRAIL-R2. Therefore, our current findings expand previous data showing that CD40-mediated immune activation sensitizes B-CLL cells to CD95 ligand (CD95L) and TRAIL-mediated killing [22, 23] , suggesting that the combination of immune activation plus Nutlin-3 might further increase the susceptibility of B-CLL to CD95L and TRAIL.
Thus, our present data suggest that a strategy of association between CpG-ODN and Nutlin-3 might be effective in achieving an efficient immune activation and to restrain the proliferative potential of CpG-ODN treatment in B-CLL samples, irrespective of its Zap-70 status.
